Paradigm Therapeutics
Manufacturing · South Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
465 W Coleman Blvd Ste 202, Mount Pleasa...Website
www.paradigmtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Paradigm Therapeutics
Paradigm Therapeutics is a biopharmaceutical company dedicated to improving the lives of patients with life-threatening diseases through innovative therapies. Their lead product, Zorblisa, is a proprietary topical therapy aimed at treating Epidermolysis Bullosa (EB), a rare genetic disorder. The company's efforts are focused on addressing the significant therapeutic needs of EB patients, particularly in areas such as wound healing and infection management. Paradigm Therapeutics recently expanded its portfolio by acquiring a late-stage breakthrough therapy for all subtypes of EB, enhancing its commitment to patient care.Explore more
Paradigm Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Paradigm Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Paradigm Therapeutics has new funding data
Check out if Paradigm Therapeutics is spiking on competitors!
Earning: See what the market has to say on Paradigm Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Paradigm Therapeutics
Check if Paradigm Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Paradigm Therapeutics launches new products
Click to see if Paradigm Therapeutics had a recent Job posting/layoffs
Paradigm Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Paradigm Therapeutics
Find 3 more new buyers
Compare Similar Companies to Paradigm Therapeutics
Compare insights from companies similar to Paradigm Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Paradigm Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Paradigm Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Paradigm Therapeutics.
Paradigm Therapeutics financials insights
Gather financial insights about Paradigm Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Other Financing Round
$12.6M
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Funding
Paradigm Therapeutics News & Media
Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Launch of the SD-101 Program Globally. MT PLEASANT, S....Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT...Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Paradigm Therapeutics
Sign Up For FreeTo access detailed company insights
Paradigm Therapeutics is a biopharmaceutical company dedicated to improving the lives of patients with life-threatening diseases through innovative therapies. Their lead product, Zorblisa, is a proprietary topical therapy aimed at treating Epidermolysis Bullosa (EB), a rare genetic disorder. The company's efforts are focused on addressing the signi... Read More
